Status: Recruiting
Amping up With PemJAK
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
Participants needed: 53
Trial details
Phase: Phase 2Age: 18-95Biological sex: AllType: InterventionalSponsor: Seda S. ToluUpdated: Dec 16, 2025Locations: 1
Eligibility criteria
Arm 1: PTCL [+41]
1) Diagnosis of Adult T-Cell Leukemia/Lymphoma (ATLL) [+17]